Niki BioSolutions, Inc. · NASDAQ:NIKI
Niki BioSolutions — Aptorum Group — Investor Presentation (May 2019)
16 slides from Niki BioSolutions's investor presentation, May 31, 2019
Slide 1: Aptorum Corporate Presentation
APTORUM OUR MISSION IS TO FACILITATE LIFE SCIENCE INNOVATIONS TO SERVE UNMET MEDICAL NEEDS. Corporate Presentation NASDAQ Global Market: APM
Slide 2: Listed on NASDAQ (APM) on 18 December 2018
eh 4050 1200 ASL 5S 110 touatlS? 55621 ‘On 18th December 2018, Aptorum Group Limited listed on the NASDAQ (ticker symbol: APM). IPO stock price is USD 15.80. Latest stock y NasdaqListed price is over USD 28.00 with current at se _ Market capital of over USD 800 M. 2 fereeame panos
Slide 3: The Expanding Universe of Aptorum
‘The Expanding Universe of Aptorum ® Acticule: Non-Antibiotic Platform Claves: Pioneering Druggable Platform in robiome Accelerating drug development via systematic drug, repurposing for orphan diseases Ever expanding universe of drug IP v Foriazate pupae eno guatcect an pecbng canseedathavegs neste
Slide 4: The Mechanisms of ALS-4
THE MECHANISMS OF ALS-4 ANTI-GOLDEN PIGMENT AGENT drone = ” ee + Staphyloxanthin is the golden yellow pigment of S. Ankbenvarny aureus see 6h 4 + The pigment protects the bacteria against oxidative E dak Aaa AUS4 stress produced by our immune cells. E: porise oles ean + ALS-4is intended to suppress
Slide 5: In vivo and in vitro Efficacy of ALS-4
in vivo AND in vitroEFFICACY OF ALS-4 ALS-4 is observed to reduce bacterial load in mice ALS-4 is intended to inhibit S. aureus pigment production with an ICyp = 20nM Acute treatment 7 Inoculum: 5 X 10° per mouse . Delayed treatment DMSO Control ALS-4 SG GIE © © wm @ @ @\e & & 1m™ é ) & 50 nM. aon .
Slide 6: Microbiota and Diseases
Microbiota and Diseases = <——SEEe Diseases Associated with Microbiota Digestive diseases Systemic diseases = C. difficile infection « Obesity » Colorectal cancer = Diabetes « Inflammatory bowel disease « Fatty liver « Irritable bowel syndrome » Cardiovascular diseases » Renal failure = Depression «
Slide 7: Gut Microbiota: Our Strategy
Gut Microbiota <—— Our Strategy 1. Novel therapeutics to reduce amount of harmful gut microbiota chemicals that cause diseases Act in gut with high affinity and specificity Non-absorbable and free from systemic toxicity Hundreds of metabolites for various clinical indications Sustainable pipeline of
Slide 8: Smart-Act: Accelerating the Commercialization of Therapeutics
Smart At ee Smart-Act: Accelerating the Commercialization of Therapeutics ne APTORUM= 8B —_ferheramepumoseny mer
Slide 9: ACT - Accelerating the Commercialisation of Therapeutics
ACT- Accelerating the Commercialisation of Therapeutics Traditional 3D piscoverY PRECUNICAL PHASE 1 PHASE PHASE AcT3D ‘COMPUTATIONAL ALGORITHMS AND BIG DATA Protein docking, genetic simulation, immunology, genomics, biolmaging, animal studies, proteomics @ REPURPOSE Potentially skip preclinical and
Slide 10: Traditional 3D & ACT 3D
TRADITIONAL 3D & ACT 3D. ‘Traditional 30 - Problems 10417 years! 5-65 years Drug Discovery: 310 years? Drug Discovery: 1-1.5 year ‘Time (years) __Precinical Development: 1 year Preclinical Development: may not needed Phase : Several months? Phase : May not needed Phase il to market: 5.4 years! Phase
Slide 11: Life Examples: Neuroblastoma
LIFE EXAMPLES: Neuroblastoma adage aougsdeiie 2 dragsdened Wet Lab Validation 2019 Phase 3 Trial Done 2001 Regulatory Approval 2004 Commercialisation 2025 Total 6 years" “mein erste essen estomrgansee my ‘as mths ang nites ih eo ACT moe gps Nae ‘roracnton tee sy sce sun dns oat seep ome et Foriazate
Slide 12: ACT - Accelerating the Commercialisation of Therapeutics
ACT- Accelerating the Commercialisation of Therapeutics como 209 ton Gin mo APTORUME
Slide 13: ACT - Accelerating the Commercialisation of Therapeutics
ACT- Accelerating the Commercialisation of Therap (S Caneeretion + Ot caring Manetsatan rate ‘rohan Diseases 7000 5~10tcanddates potently enter Hrd ange ain Sh cal aaah year Ppoine nm oramiccmonnes fencers 080 a + expect ein aset n 20208 » 00 ‘camultvly 4 linia assets! by 2028, os 1000 Potential Ass
Slide 14: APM Stock Performance (as of 27/5/2019)
APM Stock Performance (as of 27/5/2019) ‘Announcement of Inclusion in MSCI | a Hong Kong Micro Cap 210 Index [2800 ‘Announcement of launching Claves Platform =o Announcement of f 21.00 USD 90 M Agreement | sts with A*STAR | Announcement of launching Smart-Act™ 1700 Platform 16.00 2019 feb mat apr ma
Slide 15: Disclaimer
RES CA UM Certain information included in this presentation and other statements or materials published by Aptorum Group Limited (the "Company’) are not historical facts but are forward-looking statements. ‘These forward-looking statements refer in particular to the Company's management's business s
Slide 16: Aptorum Group Limited
APTORUM= ‘APTORUM GROUP LIMITED westoraltions @aptorum, 2 1 485221176611 F +85228507285